# EMERGENT BIOSOLUTIONS INC. (EBS) · Edgar & Edgarette company card

> Emergent Biosolutions (EBS) saw revenue fall 28.8% in FY2025 to $743 million, operating margin 13.5% against a -3.8% median for pharmaceutical preparations, equity 39.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1367644 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/EBS) · [JSON](https://www.pops4.com/boards/company/EBS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $743M |
| Revenue growth, 1 year | -28.8% |
| Revenue growth per year | -19.6% |
| Operating margin | 13.5% (prior year -10.4%) |
| Net margin | 7.1% |
| Operating cash flow | $171M |
| Capital spending | $14M |
| Free cash flow | $157M |
| Cash | $205M |
| Long-term debt | $590M |
| Total assets | $1.3B |
| Total equity | $523M |
| Equity ÷ assets | 39.6% |
| Return on equity | 10.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 3.44 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -3.56 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · filed restructuring or exit costs in the last 12 months; slow and jumpy: growing slower than its size class, with revenue that swings more; revenue is hard to predict: its 80% range is ±27%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $742.9M (FY2025), total debt $589.7M. Experience: revenue down 28.8% on the year, down 19.6% a year over 4 years; operating margin 13.5%, up from -10.4%. Soundness: equity 39.6% of assets, return on equity 10.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $437.2M and $765.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $379.5M to $886.5M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 13.5% against a -3.8% median; growth -28.8% against 13.7%.

Range logged 2026-10-19, receipt 9435d5a6c2f24748, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-08-05 ([filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/0001367644-26-000080-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-10-16 ([filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm))

## Recent filings

- 8-K · filed 2026-11-04 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000116/0001367644-26-000116-index.htm)
- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000112/0001367644-26-000112-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000110/0001367644-26-000110-index.htm)
- 8-K · filed 2026-10-16 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000098/0001367644-26-000098-index.htm)
- 8-K · filed 2026-09-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000091/0001367644-26-000091-index.htm)
- 8-K · filed 2026-09-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/0001367644-26-000088-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001367644.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1367644

## Cite

POPS4, Edgar & Edgarette: EMERGENT BIOSOLUTIONS INC. (EBS) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/EBS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

